Glaukos Corporation (GKOS) had a rough trading day for Friday September 27 as shares tumbled 7.85%, or a loss of $-5.21 per share, to close at $61.17. After opening the day at $66.05, shares of Glaukos Corporation traded as high as $66.86 and as low as $60.58. Volume was 765,688 shares over 8,366 trades, against an average daily volume of n/a shares and a total float of 36.83 million.
As a result of the decline, Glaukos Corporation now has a market cap of $2.25 billion. In the last year, shares of Glaukos Corporation have traded between a range of $84.65 and $50.60, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
Glaukos Corporation is based out of San Clemente, CA and has some 437 employees. Its CEO is Thomas W. Burns.
